G LUCOCORTICOIDS (GCs) are a class of steroid hormones with a broad spectrum of physiological effects. Pharmacologically, GCs are efficiently used for antiinflammatory and immunosuppressive therapies. Most of the biological activities are mediated via the glucocorticoid receptor (GR), a member of the superfamily of nuclear hormone receptors (1) . Some of the GR-dependent effects on gene transcription have been attributed to ligand-bound GRs and their specific interaction with the corresponding conserved DNA motifs, delineated as glucocorticoidresponsive elements (GREs). However, many genes transcriptionally suppressed by GCs, do not contain GREs within their promoters. Therefore, alternative mechanisms were proposed to account for GCdependent inhibition of gene expression.
One common mechanism is thought to arise from mutual interaction between GR and transcriptional activators as reported for activator protein-1 (AP-1) (2), nuclear factor B (NF-B) (3, 4) , CCAAT/enhancer binding protein, and signal transducer and activator of transcription 5 (5) . All of these transcription factors are essentially involved in the up-regulation of proinflammatory genes, including those for cytokines, chemokines, adhesion molecules, and enzymes. The latter ones involve the matrix metalloproteinases (MMPs), a family of zinc-dependent, neutral proteases degrading specifically components of the extracellular matrix (ECM). MMPs have been implicated in a variety of diseases accompanied with an altered turnover of the ECM (6) . In the kidney, a dysregulation of ECM turnover considerably affects the mechanical and functional integrity of the glomerulus, finally leading to the impairment of glomerular filtration (7) . Accumulation of ECM proteins, for example, is a hallmark of progressive renal diseases, such as diabetic nephropathy and other conditions leading to glomerulosclerosis (8) .
We studied the effects of GCs on cytokine-induced MMP-9 (92-kDa type IV collagenase) expression in rat renal mesangial cells (MCs) because the altered expression of MMP-9 is thought to be a key event in the pathological remodeling of glomerular ECM leading to glomerulosclerosis.
Expression of MMP-9 is regulated by various stimuli including mitogens, growth factors, activators of receptor tyrosine kinases, oncoproteins of the Ras family, phorbol esters, and inflammatory cytokines (9-13). Recently, we and others have shown that proximal AP-1 and NF-B sites within a 0.6-kb fragment of the MMP-9 promoter region are necessary and sufficient for IL-1␤-dependent MMP-9 promoter activation in rat MCs (11, 14) . We now report on an additional functional region located further upstream and encompassing a binding site for Ets transcription factors in close neighborhood to a second AP-1 site. Ets is a member of a transcription factor family identified on the basis of high homology to the v-Ets oncogene. Members of this family are functionally important for angiogenesis and, therefore, suggested to be involved in the pathogenesis of a number of diseases, including rheumatoid arthritis, diabetic retinopathy, and cancer. Ets proteins are functionally highly diverse because they participate in a variety of cellular events including transcriptional regulation, DNA replication, and growth control (15) . Ets proteins can mediate transcriptional activation as monomers or in complexes with other transcriptional regulators, e.g. Elk-1 (16) . Interestingly, binding sites for Ets are highly conserved in the promoters of different MMPs. Ets-related proteins have been identified as a target for a negative regulation of MMP-1 (collagenase) expression by interaction with the androgen receptor (17) . In this study we show that inhibition of MMP-9 expression by GCs is largely due to a diminished transactivation and a reduced binding activity of NF-B and Ets-containing complexes within the 5Ј-flanking region of the MMP-9 gene independent from a DNA binding to a GRE.
RESULTS

Dexamethasone Reduces the Lytic Activity and Total Levels of MMP-9 in Rat MCs
To evaluate possible effects of dexamethasone on the lytic content in the conditioned media from cytokinetreated cells, we performed incubations with IL-1␤ (2 nM) in the presence of vehicle (control) or dexamethasone (100 nM) or a combination of dexamethasone plus a 10-fold molar excess of the GR antagonist mifepristone (RU-486). The gelatinolytic content of conditioned medium of MCs withdrawn after 24 h of stimulation was tested by zymography using gelatin as a substrate. As shown in Fig. 1A , supernatants of MCs under stimulatory conditions contain both gelatinases, MMP-2 and MMP-9, characterized by their different migration properties in the zymogen gel as lytic bands of 70 kDa and 92 kDa, respectively (13) . Simultaneous incubation of MCs with dexamethasone substantially reduced the IL-1␤-caused lytic activity of MMP-9. As shown previously, the lytic band migrating at 92-kDa corresponds to the inactive proform of MMP-9 (14) . The reduction in the lytical content by dexamethasone is fully reversed upon simultaneous incubation of MCs with dexamethasone and the GR antagonist RU-486, thus demonstrating that the inhibitory effects of dexamethasone are dependent on binding to the GR (Fig. 1A) .
To evaluate whether the reduced lytic activity of MMP-9 is due to a decrease in the amount of secreted MMP-9 protein, we assessed MMP-9 content in cell supernatants by Western blotting using a polyclonal anti-MMP-9 antibody. As shown in Fig. 1A (w.b. ), supernatants from untreated control cells contain low levels of MMP-9 protein whereas the amount of MMP-9 protein is much higher in the conditioned media from IL-1␤-stimulated MCs. Similar to the effects observed by zymography, conditioned media derived from dexamethasone-treated MCs showed a significant reduced content of MMP-9 protein (Fig. 1A, lower  panel) . The conditioned media from MCs cotreated with dexamethasone and RU-486 again contained high MMP-9 protein levels. Therefore, we conclude that the dexamethasone-mediated alterations of zymogen activity predominantly result from changes in the MMP-9 expression levels. Consistent with these observations, dexamethasone did not directly alter MMP-9 activity as monitored by in vitro zymography (data not shown).
Dexamethasone Attenuates Cytokine-Induced MMP-9 mRNA Steady-State Level
Next we performed Northern blot analysis using a cDNA probe from the rat MMP-9 gene (13). MCs were stimulated for 24 h with IL-1␤ (2 nM) in the presence of vehicle (control), or dexamethasone (100 nM), with or without RU-486 (1 M), before RNA extraction. As shown in Fig. 1B , the IL-1␤-caused increase in MMP-9 mRNA steady-state level was almost totally blocked by dexamethasone (from 11.8 Ϯ 3.5-fold to 2.7 Ϯ 0.6-fold induction; mean Ϯ SD, n ϭ 4), whereas coincubation with RU-486 partially reversed the dexamethasone-mediated inhibition.
Furthermore, we found that other glucocorticoids (GCs), including prednisolone, fluocinolone, and hydroxycortisone, potently reduced the cytokine-mediated increase in MMP-9 mRNA level and gelatinolytic content (data not shown). Similar to the different glucocorticoids the mineralocorticoid aldosterone (100 nM) had strong inhibitory effects on the cytokineinduced MMP-9 mRNA level. By contrast, the sex steroids estradiol and testosterone had no effects on either the basal or the cytokine-induced MMP-9 mRNA levels (data not shown).
Cloning of the 5-Flanking Region of the Rat MMP-9 Gene
To further elucidate the downstream targets of glucocorticoid-mediated inhibition of MMP-9 expression, we cloned a 1.3-kb promoter fragment of the rat MMP-9 gene by "gene walking" using MMP-9 genespecific antisense primers as described in Materials and Methods. The sequence was subjected to computational analysis using the HUSAR software package (Transfac 3.5). Computer analysis revealed the presence of a TATA box-like sequence preceded by a multitude of putative transcription factor binding site consensus sequences, possibly involved in the regulation of MMP-9 gene transcription by cytokines. These include binding sites for AP-1, NF-B, Myb, peroxisome proliferator-activated receptors, and nuclear factor of IL-6. The sequence and DNA boxes are depicted in Fig. 2, A and B.
Inhibition of Rat MMP-9 Promoter Reporter Constructs by Dexamethasone
As described previously, a 0.6-kb fragment of the rat MMP-9 promoter is sufficient for induction of the MMP-9 reporter gene by IL-1␤ (14) . Comparison of IL-1␤-induced luciferase activities of the long 1.3-kb MMP-9 promoter fragment (pGL-MMP-9-⌬1.3) with the shorter 0.6-kb fragment (pGL-MMP-9-⌬0.6) revealed that pGL-MMP-9-⌬0.6 retained a relative promoter inducibility indistinguishable from that of the long promoter fragment pGL-MMP-9-⌬1.3, although luciferase activities of pGL-MMP-9-⌬0.6 displayed an overall reduced level of total activity (Fig. 2C ). These data suggest that elements laying between Ϫ1378 and Ϫ597 contribute mainly to the basal promoter activity of the MMP-9 gene, but the proximal promoter sequence up to Ϫ597 contains the positive elements that confer MMP-9 promoter induction by IL-1␤. Treatment of MCs with dexamethasone resulted in a nearly complete inhibition of cytokine-induced luciferase activities with both MMP-9 promoter constructs (Fig. 2C) . RU-486, similar to dexamethasone, had no significant effects on basal promoter activities (data not shown).
Involvement of NF-B and Ets Binding Sites in the Activation of the Rat MMP-9 Gene Promoter by IL-1␤
From the data presented in Fig. 2 , we suggest that GC-sensitive regions are mainly positioned in a region downstream from Ϫ597. This promoter region, in addition to binding sites for NF-B and AP-1, contains a further binding site for an Ets transcription factor ad- . Twenty-four hours after stimulation, 10 l of supernatant were subjected to SDS-PAGE zymography (upper panel). The concentrations used were: IL-1␤, 2 nM; Dex, 100 nM; RU-486, 1 M. Western blot analysis of trichloroacetic acid precipitated MMP-9 in the same supernatants as used for zymography (lower panel). For immunodetection of MMP-9, 100 g of total protein were subjected to Western blot analysis (w.b.) using a polyclonal antibody raised against MMP-9. Migration properties were determined using standard molecular weight markers. The data are representative of four independent experiments with similar results and are graphically shown in the lower panel. B, Inhibitory effects on the IL-1␤-induced MMP-9 mRNA steady-state level by dexamethasone (Dex) are reversed by RU-486. Total cellular RNA (20 g) was hybridized to a 32 P-labeled cDNA insert from KS-MMP-9 and analyzed by Northern blot analysis (n.b.) Equivalent loading of RNA was ascertained by rehybridization to a GAPDH probe. An analysis of four independent experiments is shown in the lower panel. Results are expressed as means Ϯ SD (gray filled bars; n ϭ 6) and are presented as fold induction. P Յ 0.05 compared with control conditions (*) or to IL-1␤-stimulated values (#). P Յ 0.01 (**), (##).
jacent to a second distal AP-1 response element (Fig.  3A) . Adjacent Ets and AP-1 binding sites have also been reported for the promoters of other matrix proteases, including collagenase I, stromelysin (18) , and human urokinase plasminogen activator (19) . Moreover, Ets has also been identified as a target for the negative regulation of MMP-1 expression by androgens in the human prostate carcinoma cell line DU 145 (17) .
To further localize the putative transcription factor binding sites involved in the suppression by GCs, we assayed the luciferase reporter gene activities of different pGL-MMP-9-⌬1.3 constructs bearing single point mutations in the binding sites of the candidate transcription factors as indicated in Fig. 3A . A promoter analysis comparing the remaining transcriptional activities of these MMP-9 promoter constructs is summarized in Table 1 . We observed that all mutant constructs displayed an overall reduced level in total luciferase activity when compared with the wild-type MMP-9 promoter construct. However, the level of basal promoter activities of all mutants was clearly above background promoter activity as determined by measuring luciferase activity of a promoterless pGL basic reporter gene (Table 1) . Previously, we have demonstrated that promoter activation of pGL-MMP-9-⌬0.6 by IL-1␤ critically depends on an AP-1 (Ϫ87/ A, Sequence analysis of the rat MMP-9 5Ј-flanking region. Potential binding sites for transcription factors involved in cytokine signaling of MMP-9 are indicated. Numbers in brackets indicate the degree of homology to consensus sequences of transcription factor binding sites. The transcriptional start site (ϩ1) of the rat MMP-9 gene was predicted from the high degree of homology to the mouse and human genes, respectively. B, Schematic representation of two 5Ј-portions of the rat MMP-9 gene fused to the pGL-luciferase reporter gene. Base positions are numbered relative to the translational initiation site indicated by the arrow. Putative binding sites for transcription factors that potentially contribute to MMP-9 promoter activation by IL-1␤ are represented as rectangles and ovals, respectively. C, Luciferase activities of different MMP-9 promoter constructs (described above). MCs were transiently cotransfected with 0.4 g of pGL-MMP-9 (1.3 kb) or with pGL-MMP-9 (0.6 kb) and with 0.1 g of pRL-CMV coding for Renilla luciferase. After overnight transfection, MCs were treated for 24 h with vehicle (control), IL-1␤ (2 nM), dexamethasone (Dex, 100 nM), or a combination of IL-1␤ and Dex before being harvested for measuring dual luciferase activities, as described in Materials and Methods. The values for beetle luciferase were related to values for Renilla luciferase and are depicted as relative luciferase activities. Data represent means Ϯ SD (dark filled bars, n ϭ 6).
Ϫ81
) and a NF-B binding site (Ϫ560/Ϫ550) (14) . Both, AP-1 and NF-B are established targets of GRmediated suppression of a variety of inflammatory genes (5) . As shown in Fig. 3B , disruption of the NF-B site at (Ϫ560/Ϫ550) within the longer pGL-MMP-9-⌬1.3 construct completely reduced transactivation of pGL-MMP-9-⌬1.3 by IL-1␤. In contrast, disruption of the proximal AP-1 site at (Ϫ87/Ϫ81) within the 1.3-kb MMP-9 promoter fragment only moderately reduced promoter inducibility by IL-1␤ (Fig. 3B ). This observation somewhat contrasts with the finding that the same mutation within the 0.6-kb construct completely prevented promoter activation through IL-1␤ (14) . Obviously, in the context of the long promoter, the proximal AP-1 site is of minor functional importance for promoter activation by IL-1␤, but after deletion of a sequence distal from Ϫ597 it may gain impact for promoter activation and constitute IL-1␤ responsiveness. Furthermore, the distal AP-1/Ets-region (Ϫ511/Ϫ497) seems to be the functional relevant AP-1 binding site as mutation of either the Ets or the AP-1 binding site in this composite promoter region results in a complete loss of inducibility by IL-1␤ (Fig. 3B ). In summary, we conclude that in addition to the NF-B element, the region containing an Ets binding site next to a distal AP-1 element is indispensable for MMP-9 gene activation by IL-1␤.
Inhibition of NF-B by Dexamethasone Is Paralleled by a Reduced Content of Nuclear p65
To further confirm the contribution of NF-B to the dexamethasone-mediated suppression of cytokineinduced MMP-9 expression, we performed EMSA using a NF-B consensus oligonucleotide. As shown in Fig. 4A (upper panel), binding of a slow migrating, IL-1␤-inducible complex and of a fast migrating, constitutive bound complex is maximal after 30 min of cytokine treatment. By supershift analysis we found that the faster migrating complex mainly contains p50 subunits because it was strongly supershifted by antip50, whereas DNA binding was only weakly affected by an anti-p65-specific antibody (Fig. 4B ). In contrast, the slow migrating complex mainly contained p65, as indicated by the complete disappearance of the complex after anti-p65 antibody treatment, but also p50, because p50-specific antisera also impaired the DNA binding. Antibodies against c-Rel, a further member of the NF-B family, had also inhibitory effects on the binding of both complexes but did not cause a prominent supershift (Fig. 4B ). Simultaneous treatment of cells with IL-1␤ and 100 nM dexamethasone caused a total inhibition of the slower migrating complex and also slightly reduced binding of the faster migrating complex, mainly at the very early time point of 30 min (Fig. 4A, upper panel) . Coincubation of cells with IL-1␤ plus dexamethasone in the presence of RU-486 reconstituted the cytokine-induced binding of both NF-B complexes (data not shown).
In addition, we elucidated whether the dexamethasone-mediated changes in NF-B-DNA binding were attributable to a reduced nuclear translocation of NF-B. To this end we performed Western blot analysis with nuclear extracts using an anti-p65-specific antibody. Treatment of MCs with IL-1␤ is followed by appearance of p65 protein within the nuclear extracts at both time points tested. Surprisingly, dexamethasone suppressed the abundance of p65 protein in MC nuclei predominantly at the early time point of 30 min but not at the later time point of 2 h (Fig. 4A, lower  panel) . To exclude the possibility of a contamination of nuclear fractions with cytosolic proteins, we checked for the presence of GR in the nuclear extracts from MCs treated in the absence of GC. As demonstrated in Fig. 4A (lower panel) , the GR band is only detectable in the extracts from dexamethasone-treated MC prepa- A, Schematic representation of the different 1.3-kb MMP-9-luciferase constructs, either nonmutated (pGL-MMP-9-wt) or modified by single-point mutations of the indicated binding sites. The mutated nucleotides are described in Materials and Methods. B, Promoter activities of different point-mutated pGL-MMP-9-promoter constructs (described in A) after stimulation with IL-1␤ (2 nM), measured as relative luciferase activity. After overnight cotransfection with the indicated pGL-MMP-9 constructs and pRL-CMV, MCs were treated for 24 h with or without IL-1␤ (2 nM) before being harvested for measuring dual luciferase activities. The values for beetle luciferase were related to values for Renilla luciferase and are depicted as relative luciferase activities. The relative increase in luciferase activity by IL-1␤ compared with unstimulated cells is indicated as fold increase. Data represent means Ϯ SD (dark filled bars, n ϭ 6).
rations, thus proving the purity of the nuclear extracts examined. To further corroborate the data generated by EMSA, we finally tested promoter activities of a reporter gene bearing a tandem of five NF-B consensus motifs in front of the luciferase coding region (Fig.  4C) . Treatment of MCs with dexamethasone strongly reduced the IL-1␤-evoked increase in luciferase activity, but had no effects on basal promoter activity when tested alone (Fig. 4C) . These data convincingly demonstrate that inhibition of the NF-B-DNA binding, seen in the EMSA, functionally correlates with dexamethasone inhibition of NF-B-driven promoter activity.
Inhibition of Cytokine-Induced Degradation of IB by GCs
Activation and nuclear uptake of NF-B as a necessary prerequisite of gene transcription in many cases depend on the degradation and release of NF-B from the inhibitor of B (IB), which is regulated by the action of IB-kinase. As depicted in Fig. 5A , treatment of MCs with IL-1␤ caused a rapid decrease in cytosolic IB␣ protein levels that was maximal at 30 min after IL-1␤ treatment. Degradation of IB was partially prevented by dexamethasone mainly after 30 min of treatment, thus suggesting that the decrease in nuclear p65 protein by dexamethasone is paralleled by an attenuated degradation of IB␣. However, in none of the experiments was the inhibition of IB␣ degradation complete, thus indicating that additional mechanisms, independent from IB␣ degradation, contribute to the inhibition of NF-B DNA binding.
Dexamethasone Induces the Expression of IB in Rat MCs
Furthermore, we monitored, whether the total IB␣ protein levels were affected by dexamethasone. Transcriptional induction of IB by GCs, in some cell types, Values for beetle luciferase were related to values for Renilla luciferase depicted as relative luciferase units (RLU). Results of RLU are expressed as means Ϯ SD (n ϭ 6). Protein lysates (100 g) from cytoplasmic fractions were subjected to SDS-PAGE and immunoblotted using an anti-IB␣-specific polyclonal antibody. To correct for variations in the protein loading, the blot was stripped and reincubated with an anti-␤-actin antibody (lower panel). B, Total amount of IB␣ in quiescent MCs treated with vehicle (control), or dexamethasone (100 and 1000 nM) for the indicated time points. Protein lysates (100 g) were subjected to SDS-PAGE and immunoblotted using an anti-IB␣-specific antibody. To correct for variations in the protein loading, the blot was stripped and reincubated with an anti-␤-actin antibody (lower panel). The blot is representative for two experiments giving similar results.
is a further possible facet of cross-talk between GR and NF-B (2). Examining total protein lysates in timecourse experiments, we found that dexamethasone at two concentrations (100 nM, 1 M) caused a marked increase in the total IB␣ protein content, preferentially at 1 h and 5 h of stimulation (Fig. 5B) . This increase in total IB␣ level remained for at least 5 h but dropped back to control levels at 24 h. These data suggest that, in rat MCs, activation of IB expression or, alternatively, inhibition of its degradation are candidate mechanisms by which glucocorticoids inhibit the expression of NF-B-dependent genes.
Dexamethasone Impairs the IL-1␤-Caused Binding to AP-1 and Ets Motifs
In addition to NF-B, AP-1 is a second prominent target of GC-mediated gene repression. To further test for a possible contribution of AP-1 to dexamethasonemediated suppression of MMP-9 expression in our cell culture model, we performed EMSA. Nuclear extracts from MCs were isolated 1 h and 5 h after treatment with the indicated agents and incubated with a radioactive labeled AP-1 consensus oligonucleotide. Treatment with IL-1␤ strongly induced DNA binding of a single complex, most clearly in the nuclear extracts prepared after 1 h of stimulation (Fig. 6A) . The specificity of this DNA-bound complex was proven by competition analysis using an oligo bearing a mutated AP-1 motif as described previously (14) . As shown in Fig. 6A , dexamethasone strongly attenuated the IL-1␤-stimulated binding of this complex to the AP-1 motif but had no effects on basal AP-1 binding. These data indicate that in rat MCs, in addition to NF-B, the cytokine-induced DNA binding of AP-1 is negatively influenced by dexamethasone.
As demonstrated before, a change of 2 bp within the putative Ets binding site drastically impaired the IL-1␤ inducibility of pGL-MMP-9-⌬1.3 (Fig. 3) . To further confirm the functionality of this binding site in the transcriptional regulation of MMP-9 gene expression by cytokines and GCs, respectively, nuclear extracts were assayed with a radioactive probe comprising the critical Ets binding site from the promoter region of MMP-9 ( Table 2) . When compared with the low basal binding affinity to AP-1, the EMSA with the genespecific Ets probe displayed a strong constitutive DNA binding of two complexes (complex I and II) that was further enhanced by IL-1␤ (Fig. 6B) .
Interestingly, the formation of the IL-1␤-inducible complexes was markedly attenuated by dexamethasone, whereas dexamethasone on its own caused a moderate increase in DNA binding, mainly of complex II (Fig. 6B, upper panel) . These results indicate that The sequences used as probes and for competition are depicted in Table 2 . For EMSA, nuclear extracts were prepared from quiescent MCs that were treated with vehicle (control), IL-1␤ (2 nM), dexamethasone (100 nM), or a combination of both agents for 60 min when a maximal induction in DNA binding activity was observed. A, The IL-1␤-induced DNA binding to a consensus AP-1 site is strongly reduced by dexamethasone, which on its own has no effect on the constitutive binding of AP-1. B, The constitutive binding of two complexes (complex I and II) to a region encompassing Ϫ518 to Ϫ491 of rat MMP-9 is further enhanced by IL-1␤ but inhibited in the presence of dexamethasone. The modulation of the DNA binding capacity is paralleled by a modulation of nuclear Ets-1 content as shown by Western blot analysis (wb) using an Ets-1-specific antibody. Similar results were obtained in three independent experiments. glucocorticoids have mixed effects on Ets-binding activity depending on the presence or absence of a simultaneous cytokine stimulus. Furthermore, the modulatory effects on DNA binding were paralleled by a change in the nuclear Ets-1 content, as assessed by Western blot analysis (Fig. 6B, lower panel; w.b.), thus indicating that the changes in DNA binding result from the changes in the amount of Ets-1 protein in the nucleus.
To prove specificity of the DNA-bound complexes, we performed supershift analysis using antibodies specific for Ets or different members of the AP-1 transcription factor family (Fig. 7A, left panel) . Binding of the slow migrating complex (complex I) was strongly impaired by addition of an antibody raised against the N-terminal domain of c-Jun, thus documenting the presence of members of the AP-1 transcription factor in the Ets-bound complex I. Interestingly, antibodies raised against Jun B and c-Fos had only very weak inhibitory effects on the DNA binding of both complexes. In contrast, the DNA binding mainly of complex I was strongly impaired by either Ets1/2 or Ets1-specific antibodies, respectively. Because DNA binding is reduced to a comparable extent by c-Jun and Ets-1-specific antibodies, we assume that complex I contains both members of transcriptional activators, whereas complex II contains none of these transcription factors.
To further characterize the DNA binding capacity of the MMP-9-specific Ets motif, we tested competition capacities of different gene-specific oligonucleotides bearing mutations either in the Ets region (Ϫ506/Ϫ511), or alternatively, a mutation in the adjacent AP-1 responsive element (Ϫ497/Ϫ504), and oligos bearing mutations in both juxtaposed core sequences ( Table 2 ). As shown in Fig. 7A (right  panel) , addition of a 100-fold molar excess of unlabeled gene-specific wild-type Ets-AP-1 oligonucleotide almost completely reduced the binding of both IL-1␤-induced DNA complexes. Competition with cold oligos bearing a mutation in either the AP-1 or Ets-1 core sequence still led to a significant decrease of 40-50% in DNA binding. Competition capacity was nearly completely lost with an oligo bearing double mutations (Fig. 7A, right panel) . These findings corroborate the data obtained by mutation analysis and indicate that a DNA binding to both consensus sites is necessary for a transcriptional activation of MMP-9 by IL-1␤.
Finally, we tested competition capacities of wildtype and mutant Ets consensus oligonucleotides. Addition of a 100-fold excess of cold wild-type Ets oligo (1:100), but not of mutant Ets oligo, caused inhibition of DNA binding of both complexes. Only a high excess of unlabeled mutant-oligo (1:10) was able to compete with DNA binding probably due to unspecific effects (Fig. 7B ).
GR Interacts with Nuclear p65 and Ets-1 Proteins
To gain further insight into the mechanism of GCdependent inhibition of the cytokine-induced activation of NF-B and Ets transcription factors in MCs, we investigated a possible physical interaction between the GR and both cytokine-inducible types of transcription factors by coimmunoprecipitation experiments. First, we studied for the association between GR and p65, by precipitation of nuclear extracts from MCs treated for 1 h with either vehicle (control) or IL-1␤ plus dexamethasone with a monoclonal anti-GR antibody. Likewise, immunoblotting of GR immunoprecipitates with a polyclonal anti-GR or a polyclonal anti-p65 antibody revealed a clear coimmunoprecipitation of p65 with GR in the cells treated with IL-1␤ and dexamethasone but not in cells exposed to vehicle (Fig. 8A) . In addition to the migration properties of p65 and the GR, which run at 65 and 92 kDa, respectively, we separated them in parallel crude nuclear extracts on the same SDS gel as positive controls (far left and right lanes of Fig. 8A ).
Most interestingly, testing the same eluates from the GR immunocomplex with an anti-Ets-1-specific antibody revealed that similarly to p65, Ets-1 was coimmunoprecipitated by the monoclonal GR antibody in the nuclear extracts from IL-1␤ and dexamethasonetreated MCs (Fig. 8B) . Furthermore, immunoblotting of the GR immunoprecipitates with anti-c-Jun did not reveal any coimmunoprecipitation of the two proteins (data not shown).
In summary, these data indicate that Ets and AP-1 motifs within the Ϫ511/Ϫ497 promoter region of MMP-9 contribute to the DNA binding capacities The position corresponding to the rat MMP-9 promoter region is indicated by numbers. Consesus sequences for AP-1 and Ets are framed, and the nucleotides that have been changed by site-directed mutagenesis are indicated as bold and underlined letters.
and are functionally important for the transcriptional activation of the MMP-9 gene by IL-1␤. Furthermore, these results demonstrate that the GR negatively interferes with p65 and Ets-1 through physical interaction also commonly denoted as transrepression.
DISCUSSION
This study aimed at the elucidation of the molecular mechanisms involved in GC-dependent modulation of MMP-9 expression. Particularly MMP-9 has been demonstrated to be involved in pathological processes underlying impaired matrix turn-over, as shown in fibrosis of lung and skin (20, 21) , and glomerulosclerosis (8) . Accordingly, we have recently identified MMP-9 as a protease that is markedly induced by IL-1␤ in rat glomerular MCs, a cell type that plays a key role in the pathogenesis of many glomerular diseases (22) . Several recent reports have documented the inhibition of MMP-9 expression by dexamethasone in various cell types and tissues, including the central nervous system (23) , human mucosal cells (24) , lung (25) , HT 1080 human fibrosarcoma cells (26) , and human skin (27) .
In the present study we demonstrate that reduction of IL-1␤-induced MMP-9 gelatinolytic activity by GCs is mainly caused by an inhibition of MMP-9 gene expression.
Transcriptional regulation of MMP-9 expression by IL-1␤ in MCs critically depends on the activation of NF-B and AP-1 transcription factors (11, 14) . Both transcription factors were demonstrated to be en- , Supershift analysis of IL-1␤-induced complexes binding to a promoter region from Ϫ518 to Ϫ491 of the rat MMP-9 gene. For supershift analysis, the indicated antibodies were preincubated overnight before addition of the labeled probe. Similar results were obtained in two independent experiments. The right panel depicts competition analysis using a molar excess of either unlabeled wild-type (wt-Ets-AP-1), an oligo bearing a mutation within the Ets motif (⌬Ets-AP-1), a mutation in the AP-1 site (Ets-⌬AP-1), or a double mutation within both sites (⌬Ets-⌬AP-1). The sequences of the oligos used for competition are depicted in Table 2 . For competition experiments, 10 nmol of each double-stranded unlabeled consensus oligonucleotide were diluted 1:100 before being added to the binding reaction with 32 P-labeled wild-type oligonucleotide from MMP-9 (wt-Ets-AP-1). The EMSA is representative of two independent experiments giving similar results. B, The DNA binding of both complexes is competed for with wild-type but not with mutant consensus Ets oligonucleotides. For competition, 10 nmol of the doublestranded unlabeled consensus oligonucleotide were diluted as indicated before being added to the binding reaction. The sequence of the consensus oligonucleotides used for competitions is depicted in Table 2 . The data are representative of two independent experiments giving similar results. NS, Nonspecific complex. gaged in a cross-talk with steroid receptors in a way that is independent of DNA binding (2, 5) . We have cloned and characterized a promoter region required for IL-1␤-dependent transcription of the rat MMP-9 gene. Sequencing of a 1.3-kb fragment of the 5Ј-flanking region of the rat MMP-9 gene identified several putative binding sites for regulation of MMP-9 expression by IL-1␤, including binding sites for AP-1, NF-B, and Ets transcription factors. By comparing two MMP-9 promoter fragments, we found that binding sites laying upstream of Ϫ597 are not required for promoter activation by IL-1␤. Mutational analysis of the proximal region further implicates a functional role of NF-B-, AP-1-, and Ets-binding sites in the IL-1␤ signaling triggering MMP-9 gene expression. EMSA confirmed that in MCs the binding of AP-1, NF-B, and Ets to their cognate binding sites is activated by IL-1␤. Remarkably, the GR displays both stimulatory and inhibitory effects on gene transcription. Because the GC-responsive MMP-9 promoter fragments do not contain a negative GRE, we conclude that suppression of MMP-9 transcription primarily results from a mechanism termed "tethering GRE," i.e. through a direct interaction between the GR and an activating transcription factor, independent of a direct binding of GR to DNA, as was exemplified for AP-1 and NF-B (2, 5, 28) . In line with these observations, we show that inhibition of cytokine-induced MMP-9 promoter activity by dexamethasone can be partly accounted for by decreased promoter binding of NF-B and probably is caused by a physical interaction between the GR and p65, as demonstrated by coimmunoprecipitation experiments. By EMSA we demonstrate that the rapid IL-1␤-induced binding of a p50/p65-containing NF-B complex is strongly attenuated in cells treated with dexamethasone. In addition, translocation studies revealed that the inhibitory effects of dexamethasone on p65 translocation are transient when compared with the sustained inhibitory effects observed on MMP-9 transcription, thus suggesting that NF-B is only a transient target of GC action. Suppression of NF-Bmediated gene expression is attributed to multiple mechanisms including inhibition of IB degradation and a decrease in DNA-binding affinity due to attenuation of the trans-acting potential as reported for c-Rel (29) . In various cell types, the expression of IB␣ itself has been found to be under the control of NF-B and, in addition, some reports could demonstrate induction of IB expression by GCs, although a functional GRE could not be mapped in the IB promoter (3, 30) . In line with these reports, we demonstrate an increase of total IB␣ protein by dexamethasone treatment, indicating a modulation of IB expression or, alternatively, in IB␣ degradation as possible mechanisms of GCmediated inhibition of gene expression in MCs. In this context it is worth mentioning that glucocorticoids also exert relevant posttranscriptional action on mRNA and protein stability (31) . In addition to NF-B, we could identify, by site-directed mutagenesis, a functional binding site for Ets transcription factors that is indispensable for a full transactivation of a 1.3-kb MMP-9 promoter luciferase construct by IL-1␤ (Fig. 4) . Moreover, EMSA and supershift analysis revealed that Etsrelated proteins, namely Ets-1, in combination with c-Jun, are further targets for the negative regulation of MMP-9 expression by GCs in MCs. Interestingly, an arrangement of adjacent binding sites for Ets and AP-1 transcription factors has been found in the promoters of several matrix protease genes, including MMP-1, MMP-3, MMP-9, urokinase-type plasminogen activator, and tissue inhibitor of metalloproteinase-1 (32) (33) (34) (35) (36) , therefore suggesting that in addition to AP-1, Ets plays a pivotal role in the regulation of matrix protease expression. The close neighborhood of AP-1-and Etsbinding sites allows for a cooperative binding between both types of transcription factors and is important for the synergistic interaction of the transcription factors (36) .
We found by competition assays that both binding sites show a high redundancy because mutation of For coimmunoprecipitation (IP), 100 g of nuclear extracts (NE) from MCs treated either with vehicle or with IL-1␤ (2 nM) plus dexamethasone (100 nM) for 1 h were subjected to columns that had been coupled with a monoclonal GRspecific (A) or a polyclonal Ets-1-specific (B) antibody, respectively. The eluted immunoprecipitated complexes were separated on SDS-PAGE and analyzed by Western blot analysis (wb) using the indicated antibodies. Similarly, as a positive control, 100 g of NE from IL-1␤-treated (for detection of p65 and Ets-1) or IL-1␤ plus dexamethasone-treated MCs (for detection of GR) were loaded on the same gel and probed with the indicated antibodies. The positions of the transcription factors were ascertained by using standard molecular weight markers and are depicted in brackets. The data are representative of two independent experiments giving similar results.
each binding site retained a similar level of competition capacity. This suggests that, at least in vitro, the bound complexes can similarly occupy both regulatory elements. Moreover, functionality of the 1.3-kb MMP-9 reporter gene construct strongly depends on both sites being intact, thus indicating that a possible interaction between Ets and AP-1 requires a sitespecific DNA binding to both corresponding core sequences. Notably, we found that the DNA binding capacity of the low migrating complex bound to the juxtaposed AP-1/Ets sites was significantly reduced by addition of either AP-1/c-Jun or by Ets-1-specific antibodies, indicating that both transcription factors, by simultaneously binding to a composite promoter region, may activate MMP-9 gene transcription. It is commonly assumed that interaction of Ets-and AP-1 transcription factors allows for a highly precise regulation of gene expression, most importantly of genes regulating tissue remodeling (32) (33) (34) (35) (36) .
A physical interaction between the GR and Ets-2 is necessary for the functional synergism of transcriptional activation of the rat cytochrome P-450c27 promoter (37) . Moreover, a positive integration of Ets in GC-dependent signaling confers the basal and GC induced expression of rat tyrosine aminotransferase (38) . To the best of our knowledge, we demonstrate here, for the first time, a negative interference of GC with Ets and thus demonstrate that interference between GR and Ets-dependent pathways can exhibit positive as well as negative effects on gene transcription. Similarly, the interaction of the androgen receptor by interference with Ets and AP-1 allows for a negative regulation of MMP-1, MMP-3, and MMP-7 expression (17) . Moreover, we demonstrate here that the inhibitory effects of GCs on Ets binding similar to the positive interference involve a direct interaction of GR with Ets-containing complexes as shown by coimmunoprecipitation studies.
In summary, we conclude that members of the Ets family are an additional important regulatory element in the signaling cascades of cytokine-mediated MMP-9 expression in noninvasive, nontransformed cell types. Moreover, our data indicate that the proximity between AP-1 and Ets binding motifs may determine not only the transcriptional activation by cytokines but allow for additional modulation through GR-mediated signals. The interaction of GCs with multiple signal transduction pathways, therefore, highlights the complex repertoire of regulatory events targeted by a glucocorticoid therapy.
MATERIALS AND METHODS
Human recombinant IL-1␤ was from Cell Concept (Umkirch, Germany). Dexamethasone was purchased from Calbiochem Novabiochem (Bad Soden, Germany). All other chemicals were purchased from Sigma (Deisenhofen, Germany).
Cell Culture
Rat glomerular MCs were grown in Roswell Park Memorial Institute 1640 supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine, 5 ng/ml insulin, 100 U/ml penicillin, and 100 g/ml streptomycin. Serum-free preincubations were performed in DMEM supplemented with 0.1 mg/ml of fatty acid-free BSA for 24 h before cytokine treatment. For experiments 3.0-5.0 ϫ 10 6 of MCs per 10-cm culture dish were used between passages 8 and 19. All supplements were purchased from Life Technologies, Inc./BRL (Eggenstein, Germany). The amount of dead cells was determined by trypan blue exclusion. Cell cytotoxicity was measured as described previously (13) .
cDNA Clones and Plasmids
cDNA insert for rat MMP-9 was generated as recently described (13) .
A glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA clone was generated using internal primers of coding sequence of rat GAPDH mRNA (GenBank/EMBL databases, accession no. NM 017008). A cDNA insert from mouse 18S rRNA was from Ambion, Inc. (Austin, TX).
Cloning of rat MMP-9 Promoter and Transient Transfections
The 5Ј-flanking region of the rat MMP-9 gene was cloned utilizing the Genome Walker Kit (CLONTECH Laboratories, Inc., Heidelberg, Germany) using internal (upstream) and external (downstream) primers from the rat MMP-9 cDNA (GenBank/EMBL databases, accession no. U36476) as follows:
MMP-9 internal primer: 5Ј-AGGGGCAGCAAAGCTGTA-GCCTAG-3Ј; MMP-9 external primer: 5Ј-TTTCAGGTCTCGGGGGAAG-ACCACATA-3Ј. A 1.3-kb fragment from a EcoRV cut library was isolated by PCR under stringent conditions. The fragment was subsequently subcloned into pBluescript-II KS ϩ and sequenced using the automated sequence analyzer ABI 310 (PE Applied Biosystems, Weiterstadt, Germany). The sequence has been deposited in the GenBank/EMBL databases (accession no. AJ438266). The forward and reverse primer sequences used for subcloning into pGL-III Basic vector coding for beetle luciferase (Promega Corp., Mannheim, Germany) were as follows:
5Ј-CTCACAGACTCATACGTCCCTTTA-3Ј (forward) and 5Ј-TGAGAACCGAAGCTTCT-GGGT-3Ј (reverse). Introduction of a double-point mutation into the NF-B site (GGAAT-TCCCCC to GGAATTGGCCC) to generate pGL-MMP-9-⌬NF-B was done, using the following (forward) primer: 5Ј-GGGTTGCCCCGTGGAATTGGCCCAAATCCTGC-3Ј (corresponding to a region from Ϫ572 to Ϫ541). Generation of a double transition within the Ets-binding site (GAGGAA to GAGAGA) to generate pGL-MMP-9 ⌬Ets was done using the following (forward) primer: 5Ј-GGCAGGAGAGAGAGCT-GAGTCAAAGACA-3Ј (corresponding to a region from Ϫ518 to Ϫ491). Generation of a double transition within a proximal AP-1 binding site (CTGAGTCA to CTGAGTTG) to generate pGL-MMP-9 ⌬AP-1 was done using the following (forward) primer: 5Ј-CACACACCCTGAGTTGGCGTAAGCCTG-GAGGG-3Ј (corresponding to a region from Ϫ98 to Ϫ65). Mutation of a second, distal lying AP-1 site (CTGAGTCA to CTGAGTTG) to generate pGL-MMP-9 ⌬AP-1/wtEts was performed using the following (forward) primer: 5Ј-GGCAGGAGAGGAAGCTGAGTTGAAGACA-3Ј (corresponding to a region from Ϫ518 to Ϫ491). All mutant constructs were generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). pNF-B-Luc, a cisreporting vector containing the luciferase gene driven by a TATA-box joined to five tandem repeats of NF-B binding sites, was obtained from Stratagene. Transient transfections of MCs were performed using the Effectene reagent (QIAGEN, Hilden, Germany). Transfections were performed following the manufacturer's instructions. The transfections were done as triplicates and repeated at least three times to ensure reproducibility of the results. Transfection with pRL-CMV coding for Renilla luciferase was used for control of transfection efficiencies. Luciferase activities were measured with the dual reporter gene system (Promega Corp., Madison, WI) using an automated chemiluminescence detector (Berthold, Bad Wildbad, Germany).
Northern Blot Analysis
Total cellular RNA was extracted from MCs using the Tri reagent (Sigma, St. Louis, MO). Procedures for RNA hybridization were as described previously (13) .
SDS-PAGE Zymography
Assessment of gelatinolytic activity of proteins from cellular supernatants was performed as described previously (13) . To exclude the possibility that alterations in gelatinolytic contents were due to differences in cell numbers, we routinely determined total cell numbers under each of the experimental conditions. Proteins with gelatinolytic activity were visualized as areas of lytic activity on an otherwise blue gel. Migration properties of proteins were determined by comparison with that of prestained full range rainbow protein markers (Amersham Pharmacia Biotech, Freiburg, Germany). Photographs of the gels were scanned by an imaging densitometer system from Bio-Rad Laboratories, Inc. (Mü nchen, Germany).
EMSA
Preparation of crude nuclear extracts from cultured mesangial cells and subsequent EMSA was done as described previously (39) . The cytoplasmic fractions were separated by centrifugation and used for detection of IB protein levels. Consensus oligonucleotides for NF-B and AP-1 were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Competition experiments were done by coincubation with a 10-to 100-fold excess (10-100 pmol) of unlabeled doublestranded oligonucleotide in the DNA-protein binding reaction. Wild-type and mutant consensus oligonucleotides for competition experiments were from Santa Cruz Biotechnology, Inc. The sequences for wild-type and mutant oligonucleotides coding for gene-specific binding sites are summarized in Table 2 .
Polyclonal antibodies used for supershift experiments were purchased from Santa Cruz Biotechnology, Inc. For supershift analysis, 2 l of the antibody were preincubated overnight before the binding reaction.
Western Blot Analysis
Nuclear cell extracts (20-50 g) were used for assessing nuclear import of p65. IB protein levels were analyzed using 50-100 g of total protein from the corresponding cytoplasmic fractions. Total cellular levels of IB and GR protein were analyzed using total cellular extracts (40) . Western blot analysis of different fractions was performed as described previously (14) . Detection of MMP-9 from cell supernatants was done by trichloroacetic acid precipitation (41) .
A polyclonal antibody specific for human MMP-9 was obtained from CHEMICON International (Hofheim, Germany). All other antibodies used in this study were from Santa Cruz Biotechnology, Inc.
Coimmunoprecipitation
Coimmunoprecipitations were performed by using the Seize Primary Immunoprecipitation Kit from Pierce Chemical Co. (Rockford, IL). This kit uses a chemical cross-linking of the primary antibody to avoid the interference with the antibody heavy and light chain bands on the Western blot. According to the manufacturer's protocol, 50-100 g of the antibody used for immunoprecipitation were chemically immobilized to a coupling gel that was subsequently packed onto a spin column. Nuclear extracts (250 g) were subjected to this column and incubated with gentle mixing for several hours in a cold room to allow binding of the antigen to the immobilized antibody. After several wash steps with immunoprecipitation sample buffer containing 0.025 M Tris, 0.15 M NaCl (pH 7.2), the immunoprecipitated complex was eluted from the column by addition of ImmunoPure IgG elution buffer and directly resolved on a 10% SDS-PAGE gel. The proteins were transferred to a nitrocellulose membrane and successively probed with polyclonal antibodies to p65, GR, and Ets-1, respectively. As a positive control for each transcription factor, 100 g of nuclear extracts from IL-1␤-(p65 and Ets-1) or IL-1␤ plus dexamethasone (GR)-treated MCs were directly subjected to the same gel used for resolution of the immunoprecipitated complexes and analyzed by immunoblotting. All antibodies used for immunoprecipitations were obtained from Santa Cruz Biotechnology, Inc.
Migration properties of proteins were determined by comparison with that of prestained full range rainbow protein markers (Amersham Pharmacia Biotech, Arlington Heights, IL).
Statistical Analysis
Results are expressed as means Ϯ SD. The data are presented as x-fold induction compared with control conditions or compared with IL-1␤-stimulated values (#). Statistical analysis was performed using Student's t test and ANOVA for significance.
